Table 1 Common characteristics of the studies

E4181/E5181 (1996)

NR

Full article

TAM 5y

TAM 5y

100

Premenopausal /Postmenopausal

100/100

73% ER+

DFS

TAM 5y

93

93/93

NSABP-B14 (2001)

III

Full article

TAM 5y

TAM 5y

593

Premenopausal /perimenopausal /Postmenopausal

Negative

ER+

DFS

TAM 5y

Placebo 5y

579

Negative

ER+

Scottish trial (2001)

NR

Full article

TAM 5y

TAM 5y

173

Premenopausal /Postmenopausal

43/90a

66/173b

DFS

TAM 5y

169

35/89

66/169

ATLAS (2013)

III

Full article

TAM 5y

TAM 5y

3428

Premenopausal /perimenopausal /Postmenopausal

1474/3428

ER+

DFS

TAM 5y

3418

1427/3418

ER+

aTTom (2013)

III

Abstract

TAM 5y

TAM 5y

3468

Premenopausal /Postmenopausal

NR

ER+/untested

DFS

TAM 5y

3485

MA.17 (2005)

III

Full article

TAM 5y

LET 5y

2593

postmenopausal

1171/2583

2516/2583

DFS

TAM 5y

Placebo 5y

2594

1189/2587

2519/2587

NSABP-B33 (2008)

III

Full article

TAM 5y

EMT 5y

799

postmenopausal

384/799

775/799

DFS

TAM 5y

Placebo 5y

799

384/779

759/799

NSABP-B42 (2016)

III

Abstract

AI 5y

LET 5y

1959

postmenopausal

NR

1959/1959

DFS

TAM 3y-AI 2y

Placebo 5y

1964

1964/1964

MA-17R (2016)

III

Full article

AI 4.5–6 y

LET 5y

959

postmenopausal

492/959

945/959

DFS

TAM-AI 4.5–6 y

Placebo 5y

959

494/959

950/959

ABCSG-6a (2007)

III

Full article

TAM5y

ANA 3y

387

postmenopausal

132/387

371/387

DFS

TAM 5y

469

146/469

454/469

DATA (S1–03) (2016)

III

Abstract

TAM 2–3y

ANA 6y

931

postmenopausal

561/827

827/827

DFS

TAM 2–3y

ANA 3y

929

551/827

833/833

IDEAL(S1–04) (2017)

III

Abstract

(AI/TAM/TAM -AI) 5y

LET 5y

NR

postmenopausal

partial positive

HR+

DFS

(AI/TAM/TAM -AI) 5y

LET 2.5y

NR